EVGN (Evogene) Cyclically Adjusted Revenue per Share: $0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EVGN Evogene Ltd EVGN
33 GF Score
Price $0.54
GF Value $0.43
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Evogene Cyclically Adjusted Revenue per Share?

Evogene EVGN -1.24% 33 Cyclically Adjusted Revenue per Share is $0.00 as of Mar. 2026. GuruFocus rates EVGN with a GF Score™ of 33/100 and a GF Value™ of $0.43 (Modestly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Evogene's adjusted revenue per share for the three months ended in Mar. 2026 was $0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Evogene's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -30.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Evogene was -30.60% per year. The lowest was -30.60% per year. And the median was -30.60% per year.

As of today (2026-07-23), Evogene's current stock price is $0.5419. Evogene's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $0.00. Evogene's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Evogene was 5.85. The lowest was 0.78. And the median was 2.49.


Evogene  (NAS:EVGN) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Evogene was 5.85. The lowest was 0.78. And the median was 2.49.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Evogene Cyclically Adjusted Revenue per Share Related Terms


Evogene Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Evogene's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evogene Cyclically Adjusted Revenue per Share Chart

Evogene Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 2.98 1.80 1.21 1.16

Evogene Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.17 1.18 1.04 1.16 0.00

EVGN vs VRTX, REGN, ALNY: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Evogene's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evogene Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evogene's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Evogene's Cyclically Adjusted PS Ratio falls into.


EVGN
33GF Score
Evogene Ltd EVGN
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evogene Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Evogene's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0/330.2130*330.2130
=0.000

Current CPI (Mar. 2026) = 330.2130.

Evogene Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.729 241.018 0.999
201609 0.601 241.428 0.822
201612 0.461 241.432 0.631
201703 0.283 243.801 0.383
201706 0.459 244.955 0.619
201709 0.290 246.819 0.388
201712 0.285 246.524 0.382
201803 0.142 249.554 0.188
201806 0.147 251.989 0.193
201809 0.143 252.439 0.187
201812 0.247 251.233 0.325
201903 0.135 254.202 0.175
201906 0.075 256.143 0.097
201909 0.038 256.759 0.049
201912 0.045 256.974 0.058
202003 0.029 258.115 0.037
202006 0.116 257.797 0.149
202009 0.117 260.280 0.148
202012 0.103 260.474 0.131
202103 0.085 264.877 0.106
202106 0.033 271.696 0.040
202109 0.037 274.310 0.045
202112 0.076 278.802 0.090
202203 0.058 287.504 0.067
202206 0.076 296.311 0.085
202209 0.113 296.808 0.126
202212 0.157 296.797 0.175
202303 0.154 301.836 0.168
202306 0.156 305.109 0.169
202309 0.767 307.789 0.823
202312 -0.409 306.746 -0.440
202403 0.824 312.332 0.871
202406 0.119 314.175 0.125
202409 0.300 315.301 0.314
202412 0.227 315.605 0.238
202503 0.360 319.799 0.372
202506 0.108 322.561 0.111
202509 0.036 324.800 0.037
202512 0.036 324.054 0.037
202603 0.000 330.213 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.00 mean?
Evogene (EVGN) has a Cyclically Adjusted Revenue per Share of $0.00 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Evogene and its competitors.
Is Evogene's Cyclically Adjusted Revenue per Share too high?
Evogene's current Cyclically Adjusted Revenue per Share is $0.00. Overall, Evogene has a GF Score™ of 33/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Evogene's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Evogene's Cyclically Adjusted Revenue per Share of $0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Evogene and its competitors. Evogene's current Cyclically Adjusted Revenue per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evogene stock overvalued right now?
Based on GuruFocus' analysis, Evogene (EVGN) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.43, compared to a current price of $0.54 — trading 26% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $0.00. Evogene's overall GF Score™ is 33/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Evogene (EVGN), the current Cyclically Adjusted Revenue per Share is $0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Evogene (EVGN) Overvalued in 2026?

Based on GuruFocus' analysis, Evogene stock appears to be overvalued. The current stock price of $0.54 is trading 26% above its estimated GF Value™ of $0.43. GuruFocus considers Evogene to be Modestly Overvalued.

Key valuation signals for EVGN:

  • Cyclically Adjusted Revenue per Share: $0.00
  • GF Value™: $0.43 vs. price of $0.54 (26% above fair value)
  • GF Score™: 33/100 with 7 warning signs

No single metric tells the full story. See the EVGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Evogene Business Description

Other Exchanges EVGN:Israel
Address 13 Gad Feinstein Street, Park Rehovot, Ness Ziona, Rehovot, ISR, 7638517
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the industrial segment, followed by Agriculture.
33GF Score

Get the complete analysis for EVGN

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.54
Price
$0.43
GF Value